Al Kildani is Senior Vice President, Investor Relations and Corporate Communications and is responsible for leading Acadia’s investor relations and corporate communications functions. He has been with Acadia since September 2023.
Mr. Kildani has a strong track record of leading investor relations and corporate communications functions at numerous growth-oriented companies across the healthcare industry, with deep experience working within companies and on Wall Street, a strong network of relationships, and proven expertise in building shareholder value.
Prior to joining Acadia in 2023, Mr. Kildani served as Vice President, Investor Relations and Corporate Communications at Halozyme Therapeutics, where he helped guide the company’s transition from early drug development stage to a profitable biopharmaceutical company. Prior to Halozyme, he oversaw investor relations and business development at Vital Therapies, Inc., and investor relations at Hologic, Inc. and Gen-Probe Incorporated. Prior to his transition to the life sciences industry, Al spent over a dozen years on Wall Street serving as an analyst and portfolio manager at Stark Investments, and previously as a sell-side analyst with C.E. Unterberg, Towbin and Pacific Growth Equities LLC.
Mr. Kildani holds a bachelor’s degree in Economics and Finance from Boston College.